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Summary
 
Memory B cells isolated from human tonsils are characterized by an activated cell surface phe-
notype, localization to mucosal epithelium, expression of somatically mutated immunoglobulin
(Ig) variable (V) region genes, and a preferential differentiation into plasma cells in vitro. In
spleens of both humans and rodents, a subset of memory B cells is believed to reside in the
marginal zone of the white pulp. Similar to tonsil-derived memory B cells, splenic marginal
zone B cells can be distinguished from naive follicular B cells by a distinct cell surface pheno-
type and by the presence of somatic mutations in their Ig V region genes. Although differences
exist between human naive and memory B cells, no cell surface molecules have been identified
that positively identify all memory B cells. In this study, we have examined the expression of
the receptor-type protein tyrosine phosphatase CD148 on human B cells. CD148
 
1
 
 B cells
present in human spleen exhibited characteristics typical of memory B cells. These included an
activated phenotype, localization to the marginal zone, the expression of somatically mutated
Ig V region genes, and the preferential differentiation into plasma cells. In contrast, CD148
 
2
 
 B
cells appeared to be naive B cells due to localization to the mantle zone, the expression of sur-
face antigens typical of unstimulated B cells, and the expression of unmutated Ig V region
genes. Interestingly, CD148
 
1
 
 B cells also coexpressed CD27, whereas CD148
 
2
 
 B cells were
CD27
 
2
 
. These results identify CD148 and CD27 as markers which positively identify memory
B cells present in human spleen. Thus, assessing expression of these molecules may be a conve-
nient way to monitor the development of memory B cell responses in immunocompromised
individuals or in vaccine trials.
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T
 
he differentiation of naive B cells into memory B cells
is a complex procedure involving antigen (Ag), Ag-
specific T cells, cytokines, and accessory cells such as den-
dritic cells and follicular dendritic cells (1–6). Ag-specific
differentiation of naive to memory B cells occurs within
germinal centers (GC),
 
1
 
 which are highly specialized areas
of secondary lymphoid areas such as lymph nodes, spleen,
and tonsil (1, 7–10). Within GC, activated naive B cells
undergo vigorous proliferation, somatic mutation of Ig V
region genes, Ig isotype switching, and selection after inter-
action with specific Ag (4, 7, 8, 11–14). Numerous B cell
subsets have been identified in tonsil, spleen, and peripheral
blood that are believed to represent different stages of de-
velopment of a naive B cell into a memory B cell.
 
 
 
In hu-
man tonsil, at least five distinct subpopulations of mature
human B cells (Bm1–Bm5) have been identified (6, 10,
14). Bm1 B cells are small resting B cells that express high
levels of surface (s)IgD. Bm2 B cells represent activated
Bm1 cells that express sIgD and the early activation Ag
CD23. Both Bm1 and Bm2 cells express unmutated Ig V
region genes (15). Bm3 cells have downregulated expres-
sion of sIgD and exhibit a high proliferative index. Somatic
hypermutation is believed to occur at the Bm3 stage of B
cell development (12, 13, 15). Bm4 cells represent differen-
tiated Bm3 cells that, depending on the affinity of their Ig
receptor after somatic hypermutation, can undergo either
positive selection or apoptosis. The cells exhibiting the
greatest affinity for Ag then develop into the Bm5 subset of
B cells, which express the downstream Ig isotypes IgG or
 
1
 
Abbreviations used in this paper:
 
 FR, framework region(s); FSC, forward
angle light scatter; GC, germinal center(s); MFI, mean fluorescence inten-
sity; MNC, mononuclear cell(s); SSC, side scatter; SAC, 
 
Staphylococcus
aureus 
 
Cowan; SLAM, signaling lymphocytic activation molecule.
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IgA as well as activation Ags such as CD80, CD86, and
CD95 (10, 14, 16). According to this criterion, naive B
cells belong to the Bm1 and Bm2 subsets, whereas the Bm5
subset corresponds to differentiated memory B cells. Naive
and memory B cells present in human tonsil also differ
from one another with respect to their anatomical distribu-
tion. Thus, memory B cells colonize the mucosal epithe-
lium, whereas naive B cells can be found within the follic-
ular area of the lymphoid tissue (16). In peripheral blood
and bone marrow, memory B cells have been identified
that express either class-switched Ig isotypes, IgM and IgD,
or IgM only (17–20). In spleen, there exist two main B cell
populations that not only are phenotypically distinct but,
similar to tonsillar B cells, also localize to separate areas of
the lymphoid tissue, namely the follicular mantle zone and
marginal zone. Mantle zone B cells primarily express an
sIgD
 
11
 
sIgM
 
1
 
CD21
 
1
 
CD23
 
1
 
 phenotype, whereas marginal
zone B cells are sIgD
 
1
 
sIgM
 
11
 
CD21
 
11
 
CD23
 
6
 
 (21–24).
Additionally, the Ig V region genes of mantle zone B cells
are unmutated, whereas those of marginal zone B cells ex-
hibit somatic mutations (25). Finally, in situ analysis of re-
sponses to T cell–dependent Ag demonstrated that mar-
ginal zone B cells were Ag-specific B cells (26). Based on
these differences, mantle zone B cells are believed to be na-
ive B cells, while marginal zone B cells are memory B cells.
Although memory B cells can be identified by the lack
of expression of sIgD and CD38 or by the expression of
switched Ig isotypes IgG and IgA (2, 3, 6, 16), this criterion
excludes non–isotype-switched memory B cells (17–20,
27). To date, no cell surface molecules have been described
that are expressed by all memory B cells. The identification
of cell surface molecules expressed exclusively by either na-
ive or memory B cells would assist in the further biological
characterization of B cell subsets, as well as in the assess-
ment of memory responses in vivo. CD148 is a receptor-
type protein tyrosine phosphatase expressed on all human
leukocytes (28). We have now examined the expression of
CD148 on human B cells and have identified CD148, as
well as CD27, as markers for memory B cells present in hu-
man spleen.
 
Materials and Methods
 
Antibodies/Cytokines.
 
The anti-CD148 mAb (28) was labeled
with FITC by established protocols. PE-labeled anti-CD148 was
prepared by PharMingen (San Diego, CA). The following mAbs
were used in this study: unconjugated, FITC-, PE-, or PerCp-
labeled anti-CD2, CD3, CD4, CD8, CD10, CD14, CD16,
CD20, CD23, CD38, CD56, CD80, and HLA-DR (Becton
Dickinson, San Jose, CA); PE-labeled anti–human IgD, IgG,
IgM, CD21, CD27, and CD86 (PharMingen); F(ab
 
9
 
)
 
2
 
 fragments
of affinity-purified goat anti–human IgD antiserum, alkaline
phosphatase–conjugated affinity-purified swine anti–goat Ig anti-
serum (BioSource International, Camarillo, CA); FITC-labeled
anti–human IgA (Sigma Chemical Co., St. Louis, MO); anti-
CD40 (mAb 89; provided by J. Banchereau, Schering-Plough
Laboratory for Immunological Research, Dardilly, France [29]);
anti–signaling lymphocytic activation molecule (SLAM; A12 [30]),
 
CD39 (A1 [30]), and CD95 (DX2 [31]). IL-2, IL-4, and IL-10
were provided by S. Menon (DNAX Research Institute of Mo-
lecular and Cellular Biology). 
 
Staphylococcus aureus 
 
Cowan (SAC)
was purchased from Calbiochem Corp. (La Jolla, CA).
 
Immunofluorescent Staining.
 
Splenic mononuclear cells (MNC)
were incubated with FITC- or PE-labeled anti-CD148 mAb,
PerCp-labeled anti-CD20 mAb, and either FITC- or PE-labeled
isotype control mAb, anti-IgM, IgD, IgG, IgA, CD10, CD21,
CD23, CD27, CD38, CD39, CD40, CD80, CD86, HLA-DR,
SLAM, or CD95 mAb on ice for 30 min. The cells were then
washed twice, fixed in 1% paraformaldehyde, and analyzed on a
FACScan
 
Ò
 
 flow cytometer (Becton Dickinson). The expression
of the different Ags was assessed by collecting data for CD20
 
1
 
cells and analyzing CD148
 
1
 
 and CD148
 
2
 
 populations of cells.
Surface staining was measured on a logarithmic scale. 1–2 
 
3
 
 10
 
4
 
events were collected per sample, and the data were analyzed us-
ing CellQuest software (Becton Dickinson).
 
Purification of Splenic B Cells.
 
Splenic MNC were depleted of
non-B cells by negative selection by incubation on ice for 30 min
with saturating amounts of anti-CD2, CD3, CD4, CD8, CD14,
CD16, and CD56 mAb. The cells were then washed twice with
PBS, mixed with an equal volume of sheep anti–mouse Ig conju-
gated to magnetic beads (Dynal A.S., Oslo, Norway), and incu-
bated on a rotating platform for 30 min at 4
 
8
 
C. Unbound cells
were collected after the removal of positive cells by a magnetic
field. Splenic B cells were further purified by cell sorting using a
FACSVantage
 
Ò
 
 or a FACStar
 
Plus
 
 (Becton Dickinson) by incubat-
ing the recovered cell population with saturating amounts of
FITC–anti-CD148 and PE–anti-CD20 mAbs. Gates were set to
collect CD148
 
1
 
 and CD148
 
2
 
CD20
 
1
 
 
 
B cells. Dead cells were ex-
cluded by the inclusion of propidium iodide (2 
 
m
 
g/ml). On
reanalysis, the sorted B cell subsets were always 
 
.
 
98%
CD148
 
1
 
CD20
 
1
 
 and CD148
 
2
 
CD20
 
1
 
 
 
(data not shown).
 
Giemsa Staining.
 
Sort-purified CD148
 
1
 
 and CD148
 
2
 
 splenic
B cells (4 
 
3 
 
10
 
4
 
) were cytocentrifuged for 5 min at 500 rpm onto
microscope slides, air dried, and then fixed in methanol for 10
min at room temperature. The slides were incubated with Giemsa
stain (BDH Chemicals Ltd., Essex, UK) diluted 1:5 with distilled
H
 
2
 
O for 15 min at room temperature, then washed with distilled
water.
 
Immunohistology.
 
Serial sections of spleen tissue were incu-
bated with a control mAb, or with mAb specific for IgM or
CD27. Bound mouse mAb was visualized using a mouse Ig–spe-
cific Vectastain kit (Vector Laboratories, Inc., Burlingame, CA),
according to the manufacturer’s instructions. IgD was subse-
quently detected by the addition of goat anti-IgD antiserum and
visualized with alkaline phosphatase–conjugated affinity-purified
swine anti–goat Ig antiserum and phosphatase-specific substrate.
 
Sequence Analysis of V
 
H
 
 Genes.
 
Total RNA was isolated from
sort-purified CD148
 
1
 
 and CD148
 
2
 
 splenic B cells by guanidine
isothiocyanate extraction using the GlassMax RNA Isolation kit
(GIBCO BRL, Gaithersburg, MD). 5 
 
m
 
l of total RNA was re-
verse transcribed into cDNA using oligo-dT (Boehringer Mann-
heim Corp., Indianapolis, IN) as primer and Superscript II RNase
H
 
2
 
 Reverse Transcriptase (GIBCO BRL) in a total volume of 25
 
m
 
l containing 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM
MgCl
 
2
 
, 10 mM dithiothreitol, and 1 mM of each dNTP. The re-
verse transcription reaction was performed at 42
 
8
 
C for 90 min.
The V
 
H
 
5 and V
 
H
 
6 genes were amplified from 1 
 
m
 
l of reverse-
transcribed cDNA by PCR in a total volume of 50 
 
m
 
l containing
10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl
 
2
 
, 250
 
m
 
M of each dNTP, 1.25 U 
 
AmpliTaq
 
 DNA polymerase (Perkin-
Elmer Corp., Foster City, CA), and 50 pmol of primers corre- 
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Figure 1. CD1481 and CD1482 human B cells represent phenotypically distinct subpopulations of B cells. (A) MNC from human spleen were incu-
bated with PE-labeled anti-CD20 mAb and either FITC-labeled anti-CD148 mAb (bold histogram) or FITC-labeled isotype control IgG1 mAb (thin histo-
gram). The FITC fluorescence of CD201 B cells was assessed by flow cytometric analysis. The values represent the mean 6 SD of CD1481 B cells from
nine different donor spleens. (B) MNC from human spleen were incubated with FITC- or PE-labeled anti-CD148, PerCp-labeled anti-CD20, and one
of the following PE- or FITC-labeled mAbs: anti-IgM, anti-IgD, anti-IgA, anti-CD21, anti-CD23, anti-CD27, anti-CD39, anti-CD80, anti-CD86, or
anti-CD95. CD1481CD201 (bold histogram) and CD1482CD201 (thin histogram) cells were gated, and the fluorescence and the light scattering character-
istics of each population were assessed by flow cytometric analysis. The fluorescence of CD1481CD201 and CD1482CD201 cells incubated with an iso-
type control mAb was within the first log of the histogram plot. These results are representative of six different spleen samples.
 
sponding to the 5
 
9
 
 region of the V
 
H
 
5 or V
 
H
 
6 leader sequences
(V
 
H
 
5 ATG GGG TCA ACC GCC ATC CT; V
 
H
 
6 ATG TCT
GTC TCC TTC CTC AT) and to the 3
 
9
 
 C
 
m
 
 constant region
(GTC CTG TGC GAG GCA GCC AA; all primer sequences
were from reference 32). The PCR consisted of 35 cycles of 1
min of denaturation at 94
 
8
 
C, 1 min of annealing at 55
 
8
 
C, and 1
min of extension at 72
 
8
 
C in a thermocycler (Gene Amp 9600;
Perkin-Elmer Corp.). Amplified PCR products were purified
from agarose gels, ligated into the pCR2.1 vector (Invitrogen,
Carlsbad, CA), and used to transform TOP10F
 
9
 
 bacteria (Invitro-
gen). Individual clones were selected, expanded overnight, and
then plasmid DNA was recovered. DNA sequencing was per-
formed in both directions using the dideoxy termination tech-
nique with a Sequenase 2.0 kit (United States Biochemical Corp.,
Cleveland, OH) and by using an automated nucleic acid se-
quencer (Applied Biosystems, Inc., Foster City, CA). Forward
(ATT ACG CCA AGC TTG GTA CCG) and reverse (ATT
GGG CCC TCT AGA TGC ATG) primers that flanked the
multicloning site of the pCR2.1 vector were used for the se-
quencing reactions. Nucleotide sequences were analyzed using
the Sequencher program, and comparisons were performed using
the GenBank database.
 
B Cell Cultures.
 
For Ig secretion, 1–2.5 
 
3 
 
10
 
4 
 
sort-purified B
cells were cultured in 200 
 
m
 
l in the wells of a 96-well round-bot-
tomed culture plate with either anti-CD40 mAb (15 
 
m
 
g/ml) plus
IL-4 (400 U/ml), anti-CD40 mAb plus IL-10 (100 U/ml), and
IL-2 (100 U/ml), or SAC (0.1%) plus IL-2 with or without IL-10
or anti-CD40 mAb. B cells were cultured in four to eight repli-
cates, depending on the number of cells recovered after cell sort-
ing. The secretion of IgA, IgG, IgG
 
4
 
, IgE, and IgM were deter-
mined after 12–14 d by Ig H chain isotype-specific ELISAs (33,
 
34). For induction of differentiation of B cells into plasma cells,
sort-purified CD148
 
1
 
 and CD148
 
2
 
 splenic B cells were cultured
with anti-CD40 mAb (15 
 
m
 
g/ml), IL-2 (100 U/ml), and IL-10
(100 U/ml) for 3 d. The cells were then washed and recultured
for 3 d in medium containing IL-2 and IL-10 only (35). All cul-
tures were performed using Yssel’s medium (36) supplemented
with 10% FCS, 40 
 
m
 
g/ml transferrin (Pierce Chemical Co.,
Rockford, IL), 0.5% BSA, and 5 
 
m
 
g/ml insulin, and were carried
out at 37
 
8
 
C in 5% CO
 
2
 
.
 
Results
 
Expression of CD148 Defines Phenotypically and 
Morphologically Distinct Subpopulations of Human B Cells
 
The A3 mAb recognizes CD148, a receptor-type pro-
tein tyrosine phosphatase expressed on all human leuko-
cytes (28). In human spleen, CD148 was found to be ex-
pressed on 
 
z
 
50% of B cells (Fig. 1 
 
A
 
). Three-color
immunofluorescence revealed that the CD148
 
1
 
 and CD148
 
2
 
splenic B cells were phenotypically distinct. The expression
of different sIg isotypes and other B cell molecules by
CD148
 
1
 
 and CD148
 
2
 
 B cells differed with respect to both
the proportion of positive cells and the level of expression
of these molecules (Fig. 1 
 
B
 
, and Table 1). Thus, while
z90% of CD1482 B cells expressed a high level of sIgD,
fewer CD1481 B cells expressed sIgD, and the level of ex-
pression on CD1481 B cells was less than on CD1482 B
cells. In contrast, a greater proportion of CD1481 B cells1694 CD148 and CD27 Are Markers of Human Memory B Cells
expressed sIgM and sIgA than CD1482 B cells. Further-
more, the expression level of these Ig isotypes on CD1481
B cells was 2.5-fold greater than CD1482 B cells. The ma-
jority of CD1482 B cells expressed CD23; however,
CD271 B cells resided in the CD1481 B cell subset. CD21
and CD39 were expressed by all B cells, yet their expres-
sion was 2–5-fold greater on CD1481 B cells than on
CD1482 B cells. Similarly, although CD80, CD86, CD95,
Table 1. Cell Surface Phenotypes of CD1481 and CD1482 B Cells
CD1482 B cells CD1481 B cells
% positive MFI % positive MFI
Surface Ag
sIgM 67.9 6 17.0 55.4 6 24.0 80.3 6 11.4 131.1 6 34.3
sIgD 84.5 6 8.0 508.3 6 112 76.8 6 8.3 261.7 6 98.2
sIgG 14.5 6 7.5 335.4 6 42 15.5 6 3.0 223.3 6 93.3
sIgA 18.5 6 7.3 75.0 6 34.7 41.3 6 8.0 170 6 94.8
CD21 98.0 6 1.2 251.8 6 55.5 92.9 6 7.0 602.9 6 213.5
CD23 78.3 6 6.4 63.1 6 17.0 30.8 6 6.3 72.7 6 12.5
CD27 17.4 6 4.0 46.9 6 21.8 90.3 6 3.2 58.0 6 30
CD39 96.7 6 1.6 115.6 6 27.9 99.4 6 0.6 591.9 6 443
CD40 100 355.1 6 54 99.6 6 0.7 545.5 6 92.8
CD80 17.4 6 9.6 21.3 6 6.4 46.3 6 8.6 37.4 6 18.9
CD86 40.5 6 16.6 20.3 6 4.3 55.8 6 5.7 85.8 6 41.8
CD95 59.1 6 13.6 21.5 6 5.6 86.5 6 11.1 76.3 6 23.8
HLA-DR 99.6 6 0.7 618 6 193 99.6 6 1.0 696.5 6 233
SLAM 26.4 6 18.9 18.8 6 4.5 36.6 6 19.3 70.5 6 22.3
FSC NA 94.1 6 8.2 NA 138.6 6 14.8
SSC NA 32.0 6 5.6 NA 61.0 6 5.8
Splenic B cells were stained with FITC- or PE-labeled anti-CD148, PerCp–anti-CD20 and FITC- or PE-labeled mAbs specific for the indicated
Ag. The percentage of CD1482 and CD1481 B cells’ positive cells, as well as the mean fluorescence intensity (MFI) of the positive cell population,
of the different surface molecules was assessed by gating on CD1482CD201 or CD1481CD201 cells. Each value represents the mean 6 SD of values
obtained from flow cytometric analysis of six different donor spleens. NA, Not applicable.
Figure 2. Morphological differences between sort-purified human CD1481 and CD1482 splenic B cells. Human splenic B cells were incubated
with FITC-labeled anti-CD148 and PE-labeled anti-CD20 and sorted into CD201 B cell populations that were either CD1482 or CD1481. After
sort-purification, the (A) CD1482 B cells and (B) CD1481 B cells were cytocentrifuged onto glass slides and analyzed by Giemsa staining.1695 Tangye et al.
and SLAM were present at low levels on some CD1482 B
cells, they were expressed at a level that was also 2–5-fold
greater on an increased number of CD1481 B cells (Fig.
1  B, and Table 1). Overall, the phenotype of splenic
CD1481 B cells was
IgM11IgD1IgA1/11CD2111CD236CD271CD3911
CD801CD861CD951,
while that of splenic CD1482 B cells was
IgM1IgD11IgA2/6CD211CD231CD272CD391
CD806CD862CD956.
In contrast to these molecules, expression of sIgG,
CD10, CD38, CD40, HLA-DR, or bcl-2 did not differ
between CD1482 and CD1481 B cells (Table 1, and data
not shown). CD1481 and CD1482 splenic B cells also
differed morphologically. The forward and 908 angle
light-scatter (FSC and SSC), indicative of cell size and in-
ternal complexity, respectively, of CD1481 B cells was
up to twofold greater than that of CD1482 B cells (Fig. 1
B, and Table 1). These morphological differences were
further highlighted after Giemsa staining of the sort-puri-
fied B cell populations. CD1482 B cells were homoge-
neously small cells with a large nucleus, scant cytoplasm,
and very few cytoplasmic granules (Fig. 2 A). In contrast,
CD1481 B cells comprised predominantly larger cells with
large cytoplasms, eccentric nuclei, and cytoplasmic granules
(Fig. 2 B).
CD1481CD271 B cells Are Located in the Marginal Zone 
of Human Spleen
Splenic white pulp contains phenotypically distinct B cell
subsets which reside in the marginal or follicular mantle
Figure 3. Localization of CD1481CD271 and CD1482CD272 B cells in follicles of human spleen. Serial tissue sections of human spleen were incu-
bated with anti-IgD antiserum alone (blue; A and D), anti-IgD antiserum (blue) and anti-CD27 mAb (red; B and E), or anti-IgD antiserum (blue) and anti-
IgM mAb (red; C). The anti-IgD polyclonal antibody was visualized after the addition of alkaline phosphatase–conjugated anti–goat Ig and phosphatase-
specific substrate. The anti-CD27 or anti-IgM mAb was visualized by an anti–mouse Ig-specific Vectastain kit. Original magnification of A, B, and C:
340; of D and E: 3100. The follicular mantle zone (FM), marginal zone (MZ), germinal center (G or GC), and T cell zones (T) are indicated.1696 CD148 and CD27 Are Markers of Human Memory B Cells
zones (21–24, 37). The phenotype of CD1482 and CD1481
B cells strongly suggested that these cells were mantle and
marginal zone B cells, respectively. To confirm that the B
cell subsets resided in distinct areas of human spleen, tissue
sections were stained with anti-IgD–specific antiserum alone
or in conjunction with either anti-CD27 mAb (to identify
sIgD11CD272CD1482 and sIgD6/1CD271CD1481 B
cells) or anti-IgM mAb (to identify sIgM1IgD11CD1482
Figure 4.1697 Tangye et al.
Figure 4. Nucleotide sequence of Ig VH5 genes isolated from CD1482 and CD1481 splenic B cells. Nucleotide sequences of VH5 Ig genes cloned
from sort-purified CD1482 and CD1481 human splenic B cells are shown. The germline VH5 (VH251) sequence was derived from Tomlinson et al. (ref-
erence 40). For clarity, only sequences homologous to VH251 are shown. Each dash represents identity with the germ-line sequence; nucleotide differ-
ences are indicated. The FR and CDRs are indicated.
and sIgM11IgD1CD1481 B cells). This was done because
these molecules defined CD1481 and CD1482 B cells (Fig.
1 B, and Table 1) and also because the A3 mAb did not re-
act well with tissue sections (data not shown). Consistent
with previous data (21, 24, 37), the mantle and marginal
zones could be distinguished by the presence of sIgDhigh
and sIgDdim B cells, respectively (Fig. 3, A and D). Within
the mantle zone is a GC, containing sIgD2 cells (Fig. 3, A
and D). The marginal zone is interrupted by the (sIgD2) T
cell zone (Fig. 3 A). CD271 cells were present in the T cell
zone, the marginal zone, and the GC, but not the mantle
zone (Fig. 3, B and E). Within the marginal zone, all sIgDdim
B cells were CD271, whereas the T cell zone comprised
single-stained CD271 cells (Fig. 3, B and E). The CD271
cells in the GC may represent T cells (38), GC B cells (39),
or both. B cells expressing the brightest level of sIgM were
present in the marginal zone, whereas mantle zone B cells
expressed a lower level of sIgM (Fig. 3 C). Similar to the
lack of expression of CD27, few sIgMhigh cells were de-
tected in the follicular mantle zone (Fig. 3 C). Thus,
CD271 B cells are sIgDdimsIgMhigh and reside in the mar-
ginal zone, whereas CD272 B cells are sIgDhighsIgMdim and
occupy the follicular mantle zone. Extrapolating these dif-
ferences to those observed for cell surface phenotypes (Fig.
1 B, and Table 1) indicates that CD1481 and CD1482 B
cells are marginal and mantle zone B cells, respectively.
CD1481CD271 B Cells Express Somatically Mutated Ig 
V Genes whereas Ig V Genes from CD1482 CD272 B 
Cells Are in Germ-line Configuration
To investigate somatic mutation, Ig V region genes be-
longing to the small VH5 family and nonpolymorphic VH6
family were amplified by PCR using 59 family-specific
leader sequence primers and a 39 C m  constant region
primer. Of 12 VH5 genes amplified from CD1482 B cells,
6 were 100% identical to 1 of the 2 published VH5 germ-
line genes (VH251 or VH32; Fig. 4 [40]). Similarly, five out
of eight VH6 gene sequences obtained from CD1482 B
cells were unmutated, and therefore identical to the single
VH6 germ-line gene here identified (VHVI; Fig. 5 [40]). No
mutations were detected in the CDR1, CDR2, or frame-
work region (FR)2 of the remaining sequences analyzed.
However, a small number of mutations were present in FR1
and FR3 (Figs. 4 and 5). The overall frequency of mutations
(no. of nucleotide changes/no. of base pairs sequenced) in
the different VH5 and VH6 genes was 0.34 and 0.21%, re-
spectively (Fig. 6, A and B); the average number of muta-
tions detected per sequence was 1.0 6 1.35 and 0.625 6
1.06 (mean 6 SD), respectively. These rates of mutation do
not differ greatly from that reported for the endogenous er-
ror rate of Taq polymerase (1/500–1,000 bp; 0.1–0.2% [17]).
This indicates that, similar to naive and mantle zone B cells
(15, 25), the Ig V genes expressed by CD1482 B cells are
unmutated and in germ-line conformation.
For analysis of Ig V genes from CD1481 B cells, 14 dif-
ferent VH5 and 9 different VH6 genes were obtained by
PCR amplification (Figs. 4 and 5). Unlike CD1482 B cells,
nucleotide changes were detected in Ig V genes expressed
by CD1481 B cells (Figs. 4 and 5). Analysis of the Ig VH
genes isolated from CD1481 B cells revealed that 14/14
VH5 and 8/9 VH6 genes had accumulated between 1 and
16 mutations, with .60% of sequences acquiring 5 or
more mutations (Figs. 4 and 5). Somatic mutations were
present in all three FR as well as both CDRs, with the fre-
quency of mutation of the different regions of the Ig gene
as high as z8% (Fig. 6). The overall frequency of muta-
tions in the different VH5 and VH6 genes was 1.9 and 2.5%
(Fig. 6), and the average number of mutations detected per
sequence was 5.64 6 4.0 and 7.67 6 5.07, respectively.
There were a total of 79 and 69 nucleotide differences de-
tected in the different VH5 and VH6 genes, respectively,
and .60% yielded amino acid replacements (data not
shown). Thus, CD1481 B cells have undergone somatic
mutation, a characteristic of memory and marginal zone B
cells (4, 15, 20, 25).1698 CD148 and CD27 Are Markers of Human Memory B Cells
CD1481 B Cells Preferentially Differentiate to Plasma 
Cells In Vitro
Memory B cells obtained from human tonsil are biased
to differentiating into plasma B cells after in vitro activation
(35, 41). To determine whether CD1482 or CD1481 B
cells preferentially differentiated to plasma cells, sort-puri-
fied B cells were cultured under conditions to induce
plasma cell differentiation (35). After the culture, z40% of
CD1481 B cells were CD381CD202, and thus resembled
plasma cells (35, 41). In contrast, only z10% of CD1482 B
Figure 5. Nucleotide se-
quence of Ig VH6 genes isolated
from CD1482 and CD1481
splenic B cells. Nucleotide se-
quences of VH6 Ig V genes
cloned from sort-purified
CD1482 and CD1481 human
splenic B cells are shown. The
germline VH6 (VHVI) sequence
was derived from Tomlinson et
al. (reference 40). Each dash rep-
resents identity with the germ-
line sequence; nucleotide differ-
ences are indicated. The FR and
CDRs are indicated.1699 Tangye et al.
cells appeared as plasma cells, while the majority (.75%)
continued to express high levels of CD20 (Fig. 7). Thus,
similar to tonsil-derived memory B cells, splenic CD1481
B cells differentiate into plasma cells at a greater rate than
CD1482 B cells.
CD1481 and CD1482 B Cell Subsets Secrete Distinct
Ig Isotypes
CD1482 B Cells Undergo Isotype Switching to Secrete IgE
and IgG4. Activation of B cells with anti-CD40 mAb and
IL-4 induces isotype switching to secrete IgG4 and IgE (2,
42). Under these conditions, CD1482 B cells secreted 87.6 6
10.1 and 89.9 6 6.3% (mean 6 SD, n 5 9), respectively,
of the IgG4 and IgE produced by total splenic B cells (Fig.
8 a). CD1482 B cells secreted 16.6 6 5.1 and 19.0 6 10.3
(mean  6 SEM, n 5 9)-fold more IgE and IgG4 than
CD1481 B cells. A similar dichotomy was observed for to-
tal IgG secretion in response to anti-CD40 mAb plus IL-4,
where it was found that CD1482 B cells secreted 6.6 6
1.2–fold more (n 5 11) IgG than CD1481 B cells (Fig. 8 a).
Thus, only CD1482 B cells are induced to undergo isotype
switching to IgE and IgG4, and secrete the majority of total
IgG, after activation with anti-CD40 mAb plus IL-4.
Differential Secretion of IgA, IgG, and IgM. Activation with
anti-CD40 mAb plus IL-2 and IL-10 resulted in secretion
of comparable levels of total IgG by CD1482 and CD1481
B cells (Fig. 8 b). However, activated CD1481 B cells were
the main producers of IgA and IgM, secreting 4.6 6 1.3–
fold more IgA (mean 6 SEM; n 5 8) and 20.6 6 4.9–fold
more IgM (n 5 11) than CD1482 B cells (Fig. 8 b). This
indicates that CD1481 B cells can secrete high levels of
particular Ig isotypes after the appropriate in vitro activa-
tion. Activation with SAC plus IL-2 revealed that CD1482
B cells secreted 18.0 6 7.5–fold more IgG than CD1481 B
cells (n 5 5; Fig. 8 c), whereas CD1481 B cells secreted
36.0 6 16.0–fold more IgM than CD1482 B cells (n 5 5;
Fig. 8 d). The secretion of IgG by activated CD1481 B
cells and of IgM by activated CD1482 B cells could be in-
creased in the presence of IL-10, or IL-10 plus anti-CD40
mAb (Fig. 8, c and d). However, under these conditions,
secretion of IgG by CD1482 B cells and IgM by CD1481
B cells was also markedly increased, such that the levels of
IgG and IgM secreted by CD1482 and CD1481 B cells, re-
spectively, continued to exceed those secreted by CD1481
and CD1482 B cells by 6–13.0-fold (Fig. 8, c and d). This
demonstrates that under these in vitro culture conditions,
CD1482 B cells are the primary producers of IgG, whereas
CD1481 B cells secrete the majority of IgM.
Discussion
Expression of CD148 allowed the identification of two
phenotypically distinct populations of splenic B cells. CD1481
B cells were larger and expressed lower levels of sIgD and
CD23, but increased levels of sIgM, sIgA, CD21, CD39,
and the activation/costimulatory Ags CD80, CD86, CD95,
and SLAM. In contrast, CD1482 B cells are smaller cells
and express a high level of sIgD and CD23 and a lower
level of activation Ags. Coincidentally, CD27 was ex-
pressed on all CD1481 but not CD1482 B cells. In vitro
stimulation of B cells by ligating sIg or CD40 induces B
cell activation as evidenced by an increase in cell size (29,
Figure 6. Frequency of mutations in Ig V genes isolated from CD1482
and CD1481 splenic B cells. The frequency of somatic mutations in (a)
VH5 or (b) VH6 genes isolated from CD1482 (white bars) and CD1481 B
cells (black bars) was calculated as the number of nucleotide changes de-
tected per base pairs sequenced. Each value represents the mean rate of
mutation for either the entire VH5 or VH6 gene (VH), or for the different
regions (FR, CDR) of the Ig V gene for all of the VH5 and VH6 clones
analyzed.
Figure 7. CD1481 B cells differentiate into plasma cells in vitro. Sort-
purified (a) CD1481 and (b) CD1482 B cells were cultured for 3 d with
anti-CD40 mAb (15 mg/ml), IL-2 (100 U/ml), and IL-10 (100 U/ml),
and then recultured for an additional 3 d with IL-2 and IL-10. Plasma cell
differentiation was then assessed by flow cytometric analysis after immu-
nofluorescent staining with FITC–anti-CD38 mAb (x axis) and PE–anti-
CD20 mAb (y axis). The values represent the percentage of cells in each
quadrant of the dot plot. Similar results were obtained in a second experi-
ment.1700 CD148 and CD27 Are Markers of Human Memory B Cells
43) and upregulation of expression of CD80, CD86 (16,
44, 45), CD95 (46), and SLAM (47). Splenic CD1481 B
cells appear to have undergone Ag-specific T cell–mediated
activation in vivo, and therefore represent a population of
activated B cells.
Splenic white pulp comprises T cell zones, B cell folli-
cles, and marginal zones, and these areas are populated by
phenotypically distinct B cell subsets (21–24, 37). Based on
phenotype, CD1481 and CD1482 human B cells corre-
sponded to marginal and mantle zone B cells, respectively.
This was confirmed by demonstrating that CD271IgD1
IgM11(CD1481) B cells colonized the marginal zone
whereas CD272IgD11IgM1(CD1482) B cells resided in the
mantle zone. It has been suggested that mantle zone B cells
are naive B cells while the marginal zone of spleen is a de-
pot for memory B cells (25, 26). Interestingly, by virtue of
IgD, CD23, CD80, CD86, and CD95 expression, CD1482
and CD1481 splenic B cells phenotypically resembled naive
and memory B cells, respectively, isolated from peripheral
blood and tonsil (2, 16, 20). Taken together, it would ap-
pear that CD148 is expressed on human splenic memory B
cells that reside in the marginal zone, whereas naive B cells
present in the follicular mantle are CD1482.
In addition to cell surface phenotype, a key difference
between naive and memory B cells is the presence of Ag-
induced somatic mutations within Ig V region genes of
memory B cells (3, 4, 15, 20). Analysis of the mutational
status of Ig V region genes expressed by CD1482 and
CD1481 B cells revealed that CD1482 B cells expressed
unmutated Ig genes. In contrast, mutations were present in
all regions of Ig V genes isolated from CD1481 B cells.
The majority of these mutations gave rise to amino acid re-
placements, and exhibited characteristics typical of point
mutations within somatically mutated Ig V genes, i.e., a
frequent exchange of G to A, A to G, and C to T (4, 20). It
is important to emphasize that the mutation status of Ig V
genes rearranged to m H chain, and consequently of sIgM-
expressing B cells, was analyzed. Thus, consistent with pre-
vious studies (13, 20), somatic mutation can occur before
Ig H chain isotype switching. The frequency of mutations
and the average number of mutations detected per gene se-
quence within the VH5 and VH6 genes derived from
CD1481 B cells were similar to that previously reported for
Ig V genes isolated from sIgM1 memory B cells derived
from human peripheral blood, tonsil, spleen, and bone
marrow (z2.0%, and 5.0–8.5 mutations/gene sequence;
15, 17–20, 25). The presence of somatic mutations in Ig V
genes in CD1481 B cells confirms that these B cells are in-
deed memory B cells, whereas the expression of unmutated
Ig V genes by CD1482 B cells demonstrates that these cells
are unprimed naive B cells.
CD27 is a TNF superfamily member expressed on rest-
ing T cells (38) and a subset of peripheral blood and tonsil
B cells (48, 49). Based on phenotype, CD1481 splenic B
cells and CD271 peripheral blood and tonsillar B cells
shared characteristics in addition to the coexpression of
CD27. CD271 peripheral blood B cells were also larger
and expressed lower levels of sIgD but higher levels of sIgA
than CD272 B cells (48, 49). Because CD1481CD271
splenic B cells expressed mutated Ig V region genes, it
would be predicted that this would also be true for periph-
eral blood and tonsil CD271 B cells. Indeed, it has recently
been reported that IgM1IgD1CD271 peripheral blood B
cells exhibited a similar frequency (z2.0% [20]) of muta-
tions in Ig V region genes as we found for CD1481CD271
splenic B cells. Interestingly, CD271 peripheral blood B
cells, similar to human tonsil memory B cells (35, 41), dif-
ferentiate into plasma cells after in vitro activation (50). In
vitro activation of sort-purified splenic B cells induced plas-
macytoid differentiation in a greater proportion of CD1481
B cells than CD1482 B cells. These results, as well as those
of others, provided additional evidence that splenic B cells
coexpressing CD148 and CD27, as well as CD271 periph-
eral blood B cells, are memory B cells.
Figure 8.  CD1482 and CD1481 B cells differ in
their ability to secrete Igs. Sort-purified CD1481
(gray bars) and CD1482 B cells (white bars) were cul-
tured with (a) anti-CD40 mAb (15 mg/ml) and IL-4
(400 U/ml), (b) anti-CD40 mAb and IL-2 (100 U/
ml) and IL-10 (100 U/ml), or (c and d) SAC (0.01%)
plus IL-2 with or without IL-10 or anti-CD40 mAb.
The amounts of IgG, IgE, IgG4, IgA, and IgM se-
creted were determined by isotype-specific immu-
noassays after 12 d. Each value represents the mean 6
SEM of four to six replicates. The results shown are
representative of data obtained from between 5 and
11 independent experiments.1701 Tangye et al.
CD1482 and CD1481 B cells also differed in their ability
to undergo isotype switching and to secrete Ig. CD1482 B
cells secreted .80% of total IgG when cultured with SAC
plus IL-2. More striking was the observation that CD1482
cells secreted all of the IgE, IgG4, and the majority of total
IgG, when cultured with anti-CD40 mAb plus IL-4. It has
been previously reported that only CD231 B cells undergo
switching to IgE (51, 52). Therefore, it was important to
note that CD1482 IgE-secreting B cells expressed CD23.
Consistent with our proposal that CD1482 B cells are na-
ive, these cells underwent isotype switching to downstream
isotypes as described for IgDbright naive B cells obtained
from human tonsil and spleen (2, 42, 53). The inability of
CD1481 B cells to secrete IgE and IgG4 did not result from
a complete inability to secrete any Ig. In fact, after culture
with anti-CD40 mAb plus IL-10 and IL-2, CD1481 and
CD1482 B cells secreted comparable levels of IgG. Impor-
tantly, CD1481 B cells secreted all of the IgM and the ma-
jority of IgA induced by this culture condition. Addition-
ally, CD1481 cells secreted the majority of IgM in response
to SAC plus IL-2. Because a significant proportion of
CD1481 B cells expressed sIgA, it is unlikely that elevated
secretion of IgA in the presence of anti-CD40 mAb plus
IL-10 and IL-2 by CD1481 B cells is due to isotype
switching, but rather results from activation of B cells that
have already undergone isotype switching to IgA in vivo.
Thus, the Ig isotype profile of activated CD1482 and
CD1481 splenic B cells is distinct. This may reflect specific
roles that naive and memory B cells play in the humoral
immune response to different pathogens.
In conclusion, by virtue of their phenotype, localization
within the marginal zone, the presence of mutations in Ig
V region genes, and their enhanced ability to differentiate
to plasma cells, CD1481 splenic B cells are memory B cells.
In contrast, CD1482 B cells characteristically resembled
naive B cells. Thus, expression of CD148 clearly identifies
memory B cells. This feature was also found for the expres-
sion of CD27. Expression of CD27 on memory B cells is
important for differentiation because ligation of CD27 en-
hanced the rate of plasma cell development (50, 54). The
physiological significance of the expression of CD148 on
memory B cells is presently unknown. It is tempting to
speculate that it too may have a role in the subsequent dif-
ferentiation of memory B cells. The finding that CD148
and CD27 are cell surface molecules capable of defining
naive and memory splenic B cells will allow further charac-
terization of these B cell subsets, and may reveal the exact
role of CD148 in B cell activation and differentiation. Fur-
thermore, assessment of expression of CD148 and CD27
represents a useful means to quantitate the development of
a memory B cell response in vivo.
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